EUVIMEDEUVIMED entdecken
Crossref

Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study

Piero Giuseppe Meliante iD, Edoardo Covelli, Giuseppe Cimino, Roger Altomari, Irene Fatuzzo iD, Chiara Filippi, Giorgio Bandiera, Antonella Polimeni iD, Antonio Greco, Marco de Vicentiis, Serena Bertin

Clinical Otolaryngology · 2026

DOI: 10.1111/coa.70084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Otolaryngology, 2026. Verfasst von Piero Giuseppe Meliante und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, "Sant'Andrea" Hospital, "Sapienza" Univers…. Hauptthemen laut MEDLINE: Rhinosinusitis, Cystic Fibrosis, Nasal Polyps, Sinusitis. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cystic fibrosis (CF) patients often contend with chronic rhinosinusitis with nasal polyposis (CRSwNP), with higher relapse rates after surgery compared to non‐CF individuals. CRSwNP has a significant impact on their quality of life and increases pulmonary infections risk. Traditional medical and surgical interventions are frequently inadequate. Dupixent is endorsed for persistent CRSwNP following conventional treatment in non‐CF subjects; its effectiveness in CF patients remains unexplored considering that those patients are frequently affected by mixed endotypes of CRS with some type‐2 features. This study delves into the assessment of Dupixent in CF‐related CRSwNP and compares it with a matched control group.

Methods

This is a non‐randomised single‐centre trial enrolling CF patients and non‐CF controls. SNOT‐22 and NPS scores before, 1 and 6 months after therapy were documented.

Results

Dupixent exhibited a significant reduction in SNOT‐22 scores after 6 months in both CF and control groups ( V = 21, p value = 0.031, both). While NPS scores showed non‐significant improvement in CF, the control group experienced a notable reduction after 6 months ( V = 10, both; p value = 0.10; p value = 0.034, respectively). No statistical differences were observed between CF and control groups in SNOT‐22 and NPS scores after 6 months.

Conclusions

This pilot study observed Dupixent's potential in managing CRSwNP in CF patients since SNOT‐22 improvement was statistically significant and comparable to the non‐CF patients. Although NPS scores improved without statistical significance, no differences emerged between CF and control groups. Therefore, Dupixent achieved comparable results between CF and non‐CF patients suffering from CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisCystic FibrosisNasal PolypsSinusitisHumansPilot ProjectsFemaleMaleChronic DiseaseAdultTreatment OutcomeQuality of LifeAdolescentYoung Adult

Stichwörter der Autor:innen

Dupixentbiologic therapieschronic rhinosinusitiscystic fibrosisnasal polyps

Autor:innen und Institutionen

  • Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, "Sant'Andrea" Hospital, "Sapienza" University, Rome, Italy.
  • Department of Sense Organs, Faculty of Medicine and Dentistry, "Umberto I" Policlinic, "Sapienza" University, Rome, Italy.
  • Department of Otorhinolaryngology, Head and Neck Surgery - Azienda Ospedaliera dei Colli, "V. Monaldi" Hospital, Naples, Italy.
  • Department of Translational and Precision Medicine, Faculty of Medicine and Dentistry, "Umberto I" Policlinic, "Sapienza" University, Rome, Italy.
  • Oral and Maxillo Facial Sciences Department, Faculty of Medicine and Dentistry, "Umberto I" Policlinic, "Sapienza" University, Rome, Italy.

ORCID-Profile: Piero Giuseppe Meliante, Irene Fatuzzo, Antonella Polimeni

Zitieren

APA

Meliante, P. G., Covelli, E., Cimino, G., Altomari, R., Fatuzzo, I., Filippi, C., Bandiera, G., Polimeni, A., Greco, A., de Vicentiis, M., & Bertin, S. (2026). Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study. Clinical Otolaryngology. https://doi.org/10.1111/coa.70084

Vancouver

Meliante PG, Covelli E, Cimino G, Altomari R, Fatuzzo I, Filippi C, et al. Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study. Clinical Otolaryngology. 2026. doi:10.1111/coa.70084

BibTeX
@article{Meliante2026,
  author = {Meliante, Piero Giuseppe and Covelli, Edoardo and Cimino, Giuseppe and Altomari, Roger and Fatuzzo, Irene and Filippi, Chiara and Bandiera, Giorgio and Polimeni, Antonella and Greco, Antonio and de Vicentiis, Marco and Bertin, Serena},
  title = {Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study},
  journal = {Clinical Otolaryngology},
  year = {2026},
  doi = {10.1111/coa.70084}
}
Kostenlos starten →